Annual report pursuant to Section 13 and 15(d)

2. SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)

v3.10.0.1
2. SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
12 Months Ended
Apr. 30, 2018
Apr. 30, 2017
Property, Plant and Equipment [Line Items]    
Intangible assets $ 3,549,427 $ 3,549,427
Impairment of intangible assets 0 0
Research and development costs 1,997,811 1,182,251
Uninsured cash balances 772,000 3,214,000
Accumulated deficit (95,964,143) (89,135,302)
Net loss (6,828,841) $ (4,443,685)
Cell-in-a-Box [Member]    
Property, Plant and Equipment [Line Items]    
Intangible assets 1,549,427  
Diabetes License [Member]    
Property, Plant and Equipment [Line Items]    
Intangible assets $ 2,000,000  
SG Austria [Member]    
Property, Plant and Equipment [Line Items]    
Percentage investment in SG Austria 14.50%  
Research and development upfront payment $ 2,000,000